Trial Profile
Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 May 2022
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Ibrutinib
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 22 May 2022 Status changed from active, no longer recruiting to completed.
- 06 Jan 2021 Planned number of patients changed from 28 to 38.
- 06 Jan 2021 Planned End Date changed from 1 Dec 2018 to 1 Dec 2023.